Minocycline for Huntington’s disease: An open label study
- 11 March 2003
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Neurology
- Vol. 60 (5) , 883-884
- https://doi.org/10.1212/01.wnl.0000049936.85487.7a
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Minocycline prevents neurotoxicity induced by cerebrospinal fluid from patients with motor neurone diseaseBrain, 2002
- Minocycline Provides Neuroprotection AgainstN-Methyl-d-aspartate Neurotoxicity by Inhibiting MicrogliaThe Journal of Immunology, 2001
- Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington diseaseNature Medicine, 2000
- Reversal of Neuropathology and Motor Dysfunction in a Conditional Model of Huntington's DiseaseCell, 2000
- Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's diseaseNature, 1999
- Unified Huntington's disease rating scale: Reliability and consistencyMovement Disorders, 1996